To gain market access in many countries, pharmaceuticals are the subject of health-technology appraisals which include an assessment of clinical-effectiveness and cost-effectiveness. Health utilities are cardinal values that represent the strength of an individual’s preference for specific health-related outcomes. Health utilities are combined with survival estimates, and aggregated across individuals to generate quality-adjusted life years (QALYs). Once aggregated, they are then used for use in health-economic evaluations to evaluate the incremental cost-effectiveness of new interventions.
Mapi’s approach for the utility-elicitation exercise always considers the decision-makers who will assess the resulting economic analysis, and is tailored to be "fit for purpose" for such decision makers. Mapi ensures that the results of the exercise are robust and consequently publishable.
Mapi has wide experience with utility elicitation, and submissions to HTA agencies including: elicitation, mapping, and data analysis in a variety of therapeutic areas such as, oncology, musculoskeletal, and rare diseases, just to name a few.